Literature DB >> 19495867

Factors associated with local recurrence after neoadjuvant chemoradiation with total mesorectal excision for rectal cancer.

Nam-Kyu Kim1, Young-Wan Kim, Byung-Soh Min, Kang-Young Lee, Seung-Kook Sohn, Chang-Hwan Cho.   

Abstract

BACKGROUND: The purpose of the present study was to investigate risk factors associated with local recurrence in patients with locally advanced rectal cancer who received preoperative chemoradiotherapy in combination with total mesorectal excision (TME).
METHODS: Rectal cancer patients who were treated with neoadjuvant chemoradiation with TME were studied. We compared 26 patients who developed local recurrence with 119 recurrence-free patients during the follow-up period.
RESULTS: The median follow-up period was 52 months (range: 14-131 months). Based on the use of univariate and multivariate analyses, circumferential margin involvement (p = 0.02), the presence of lymphovascular or perineural invasion (p = 0.02), and positive nodal disease (p = 0.03) were contributing factors for local recurrence. The local recurrence rate was different between ypN(+) patients and ypN(-) patients with more than 12 nodes retrieved (p = 0.01). There was no difference in local recurrence rates between ypN(+) patients and ypN(-) patients with < 12 nodes (p = 0.35) or between ypN(-) patients with < 12 nodes or > or = 12 nodes (p = 0.18).
CONCLUSIONS: Patients with circumferential margin involvement, the presence of lymphovascular or perineural invasion, and positive nodal disease should be regarded as a high-risk group. We also determined that lymph node retrieval (< 12 nodes) in patients with node-negative disease was a risk factor for local recurrence.

Entities:  

Mesh:

Year:  2009        PMID: 19495867     DOI: 10.1007/s00268-009-0077-4

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  32 in total

1.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer.

Authors:  E Kapiteijn; C A Marijnen; I D Nagtegaal; H Putter; W H Steup; T Wiggers; H J Rutten; L Pahlman; B Glimelius; J H van Krieken; J W Leer; C J van de Velde
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

2.  Improved survival with preoperative radiotherapy in resectable rectal cancer.

Authors:  B Cedermark; M Dahlberg; B Glimelius; L Påhlman; L E Rutqvist; N Wilking
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

3.  Impact of preoperative radiation for rectal cancer on subsequent lymph node evaluation: a population-based analysis.

Authors:  Nancy N Baxter; Arden M Morris; David A Rothenberger; Joel E Tepper
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-02-01       Impact factor: 7.038

4.  Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer.

Authors:  Jose G Guillem; David B Chessin; Alfred M Cohen; Jinru Shia; Madhu Mazumdar; Warren Enker; Philip B Paty; Martin R Weiser; David Klimstra; Leonard Saltz; Bruce D Minsky; W Douglas Wong
Journal:  Ann Surg       Date:  2005-05       Impact factor: 12.969

5.  Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer.

Authors:  B D Minsky; A M Cohen; W E Enker; L Saltz; J G Guillem; P B Paty; D P Kelsen; N Kemeny; D Ilson; J Bass; J Conti
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

6.  Number of nodes examined and staging accuracy in colorectal carcinoma.

Authors:  J H Wong; R Severino; M B Honnebier; P Tom; T S Namiki
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

Review 7.  Surgical management of locally recurrent rectal cancer.

Authors:  P M Sagar; J H Pemberton
Journal:  Br J Surg       Date:  1996-03       Impact factor: 6.939

8.  Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival.

Authors:  Nam Kyu Kim; Seung Hyuk Baik; Jin Sil Seong; Hoguen Kim; Jae Kyung Roh; Kang Young Lee; Seung Kook Sohn; Chang Hwan Cho
Journal:  Ann Surg       Date:  2006-12       Impact factor: 12.969

9.  Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy.

Authors:  Leyo Ruo; Satish Tickoo; David S Klimstra; Bruce D Minsky; Leonard Saltz; Madhu Mazumdar; Philip B Paty; W Douglas Wong; Steven M Larson; Alfred M Cohen; Jose G Guillem
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

10.  The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma.

Authors:  Koen C M J Peeters; Corrie A M Marijnen; Iris D Nagtegaal; Elma Klein Kranenbarg; Hein Putter; Theo Wiggers; Harm Rutten; Lars Pahlman; Bengt Glimelius; Jan Willem Leer; Cornelis J H van de Velde
Journal:  Ann Surg       Date:  2007-11       Impact factor: 12.969

View more
  12 in total

1.  Number of lymph nodes after neoadjuvant therapy for rectal cancer: How many are needed?

Authors:  Stefano Scabini; Valter Ferrando
Journal:  World J Gastrointest Surg       Date:  2012-02-27

2.  Development of the 'PREDICT' score through a systematic review and meta-analysis of the predictive parameters for locoregional recurrence after total mesorectal excision.

Authors:  Sualeh Muslim Khan; Sameh Hany Emile; Samer Hani Barsom; Syed Osama Ahsan
Journal:  Updates Surg       Date:  2020-07-30

3.  Oncologic outcomes of primary and post-irradiated early stage rectal cancer: a retrospective cohort study.

Authors:  Chang-Zheng Du; Yong-Chun Chen; Yong Cai; Wei-Cheng Xue; Jin Gu
Journal:  World J Gastroenterol       Date:  2011-07-21       Impact factor: 5.742

Review 4.  Multidisciplinary treatment of rectal cancer in 2014: where are we going?

Authors:  Andrea Vignali; Paola De Nardi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

5.  Circumferential resection margins of rectal tumours post-radiotherapy: how can MRI aid surgical planning?

Authors:  E R McGlone; V Shah; C Lowdell; D Blunt; P Cohen; P M Dawson
Journal:  Tech Coloproctol       Date:  2014-07-19       Impact factor: 3.781

6.  Clinical Pattern of Recurrent Disease during the Follow-Up of Rectal Carcinoma.

Authors:  Thijs Wieldraaijer; Pascal Bruin; Laura A M Duineveld; Pieter J Tanis; Anke B Smits; Henk C P M van Weert; Jan Wind
Journal:  Dig Surg       Date:  2017-03-14       Impact factor: 2.588

7.  Prognostic Implication of Negative Lymph Node Count in ypN+ Rectal Cancer after Neoadjuvant Chemoradiotherapy and Construction of a Prediction Nomogram.

Authors:  Yanwu Sun; Yiyi Zhang; Zhekun Huang; Pan Chi
Journal:  J Gastrointest Surg       Date:  2018-09-05       Impact factor: 3.452

8.  Oncologic Impact of Fewer Than 12 Lymph Nodes in Patients Who Underwent Neoadjuvant Chemoradiation Followed by Total Mesorectal Excision for Locally Advanced Rectal Cancer.

Authors:  Woo Ram Kim; Yoon Dae Han; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  The number of retrieved lymph nodes needed for accurate staging differs based on the presence of preoperative chemoradiation for rectal cancer.

Authors:  Jeonghee Han; Gyoung Tae Noh; Shen Ann Yeo; Chinock Cheong; Min Soo Cho; Hyuk Hur; Byung Soh Min; Kang Young Lee; Nam Kyu Kim
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

10.  Coexistence of perineural invasion and lymph node metastases is a poor prognostic factor in patients with locally advanced rectal cancer after preoperative chemoradiotherapy followed by radical resection and adjuvant chemotherapy.

Authors:  Chun-Ming Huang; Ching-Wen Huang; Ming-Yii Huang; Chih-Hung Lin; Chin-Fan Chen; Yung-Sung Yeh; Cheng-Jen Ma; Chih-Jen Huang; Jaw-Yuan Wang
Journal:  Med Princ Pract       Date:  2014-07-05       Impact factor: 1.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.